✦ LIBER ✦

Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation

✍ Scribed by David S. K. Lu; Nam C. Yu; Steven S. Raman; Charles Lassman; Myron J. Tong; Carolyn Britten; Francisco Durazo; Sammy Saab; Steven Han; Richard Finn; Jonathan R. Hiatt; Ronald W. Busuttil

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 187 KB
Volume: 41
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.20688

No coin nor oath required. For personal study only.

✦ Synopsis

Orthotopic liver transplantation (OLT) can be a definitive treatment for patients with hepatocellular carcinoma (HCC). Prolonged waiting times for cadaveric livers, however, may lead to dropout from the waiting list or worsened post-OLT prognosis as a result of interval tumor progression. Percutaneous radiofrequency ablation (RFA) is widely used for local control of small unresectable HCC, but its pretransplant role remains unclear. We studied the outcome of 52 consecutive patients accepted for OLT bearing 87 HCC nodules and treated with percutaneous RFA. On initial staging, the tumor burden exceeded the Milan criteria in 10 patients. Complete tumor coagulation was observed in 74 of 87 (85.1%) nodules based on postablation imaging. After a mean of 12.7 months (range: 0.3-43.5) on the waiting list, 3 of 52 patients (5.8%) had dropped out due to tumor progression. Fortyone patients had undergone transplantation, with 1-and 3-year post-OLT survival rates of 85% and 76%, respectively. No patient developed HCC recurrence. There were three major complications in 76 RFA procedures (hepatic arterial hemorrhage, small bowel perforation, and liver decompensation salvaged by OLT), without resultant death or dropout. In conclusion, percutaneous RFA is an effective bridge to OLT for patients with compensated liver function and safely accessible tumors. Tumor-related dropout rate and post-OLT outcome compared favorably with published controls of patients with early-stage disease. This can be attributed to the efficacy of RFA in producing local cure or curbing tumor progression during the waiting period. (HEPATOLOGY 2005

📜 SIMILAR VOLUMES

Treatment of hepatocellular carcinoma in

Treatment of hepatocellular carcinoma in cirrhosis: Locoregional therapies for bridging to liver transplant

✍ Fred T. Lee Jr. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

Hepatocellular carcinoma (HCC) in the setting of cirrhosis continues to increase in both the United States and abroad because of the widespread incidence of hepatitis B and C. Before the advent of transplantation, liver resection was the only method to achieve cure. However, resection is associated

Risk factors for local recurrence of sma

Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation

✍ Yasuji Komorizono; Makoto Oketani; Katsumi Sako; Naruhiro Yamasaki; Toshihiko Sh 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

## Abstract ## BACKGROUND The objectives of this study were to clarify risk factors for local tumor recurrence and to determine which patients with hepatocellular carcinoma (HCC) are most suitable for a single session, single application of percutaneous radiofrequency (RF) ablation. ## METHODS F

A prospective study on downstaging of he

A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation

✍ Francis Y. Yao; Ryutaro Hirose; Jeanne M. LaBerge; Timothy J. Davern III; Nathan 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 211 KB

Percutaneous ablation procedures in cirr

Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence

✍ Maurizio Pompili; Vincenzo Giorgio Mirante; Gianfranco Rondinara; Luigi Rainero 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 1 views

Aims of this retrospective study were to analyze the efficacy and safety of percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA) in cirrhotic patients with hepatocellular carcinoma (HCC) submitted to orthotopic liver transplantation (OLT). We studied 40 patients undergoing OLT in w

Response to transarterial chemoembolizat

Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma

✍ Gerd Otto; Sascha Herber; Michael Heise; Ansgar W. Lohse; Christian Mönch; Ferna 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 256 KB

Criteria to select patients with hepatocellular carcinoma (HCC) for liver transplantation (LT) are based on tumor size and number of nodules rather than on tumor biology. The present study was undertaken to assess the role of transarterial chemoembolization (TACE) in selecting patients with tumors s

Ablation therapy in containing extension

Ablation therapy in containing extension of hepatocellular carcinoma: A simulative analysis of dropout from the waiting list for liver transplantation

✍ Noriyo Yamashiki; Ryosuke Tateishi; Haruhiko Yoshida; Shuichiro Shiina; Takuma T 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

The dropout from the waiting list for liver transplantation among patients with hepatocellular carcinoma (HCC) is reportedly as high as 12% to 40% per year, mostly due to tumor progression. Considering the scarcity of donor organs, it would be beneficial if we could retain them within the Milan crit